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Purpose: Advances in the understanding of the pathogenesis of retinal disorders can be facilitated by a methodology to
measure expression of proinflammatory molecules in various subsets of retinal cells.
Methods: We examined whether a multiparameter flow cytometric assay can be used to identify various subsets of retinal
cells and examine expression of molecules involved in inflammatory responses in the retina. Single-cell suspensions
freshly obtained after enzymatic digestion of normal mouse retinas were stained with antibodies against cluster of
differentiation 11b (CD11b), cluster of differentiation 31 (CD31), Glial fibrillary acidic protein (GFAP), rhodopsin, Thy-1,
and vimentin. These markers were previously shown by immunohistochemistry to label retinal microglia/macrophages,
endothelial cells, astrocytes, photoreceptors, ganglion neurons, and Müller cells respectively in normal mouse retinas.
Results: Costaining with antibodies against intercellular adhesion molecule-1 (ICAM-1) and CD40 revealed that ICAM-1
is normally expressed at various levels on all subsets of retinal cells examined. In contrast, CD40 was detected only on
CD11b+, CD31+, Thy-1+, and vimentin+ cells. Ischemia-reperfusion of the retina resulted in upregulation of ICAM-1 on
CD105+ and vimentin+ cells and upregulation of nitric oxide synthase 2 in CD11b+ cells.
Discussion: These results indicate that flow cytometry can be used to readily quantitate expression of surface and
intracellular molecules of relevance to retinopathies in freshly isolated retinal cells.
Increasing  evidence  indicates  that  inflammation  is  an
important component of the pathogenesis of retinopathies [1,
2]. Intercellular adhesion molecule-1 (ICAM-1 or CD54) and
nitric oxide synthase 2 (NOS2) are two molecules involved in
retinal disorders. ICAM-1 is an adhesion molecule expressed
on endothelial cells and leukocytes that participates in the
recruitment  of  leukocytes  to  sites  of  inflammation.
Inflammatory infiltration in the inner retina leads to retinal
injury after ischemia and reperfusion (I-R) [3]. ICAM-1 is
upregulated in the ischemic retina [1] and administration of
anti-ICAM-1 monoclonal antibody (mAb) partially prevents
injury  to  the  inner  retina  [3].  In  the  case  of  diabetic
retinopathy, the retinal vasculature expresses higher levels of
ICAM-1  [4].  Moreover,  blockade  of  ICAM-1  prevents
diabetic retinal leukostasis, vascular leakage, and vascular
histopathology [2,5].
Inflammatory stimuli in acute retinal ischemia induce
NOS2  [1].  Similarly,  NOS2  is  upregulated  in  diabetic
retinopathy  [6].  Induction  of  NOS2  is  relevant  because
administration of an NOS2 inhibitor partially protects against
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retinal thinning after ischemia and diabetic retinopathy [7,8],
and NOS2−/− mice are resistant to diabetic retinopathy [9].
CD40 is an important regulator of inflammation. CD40
is a member of the TNF receptor superfamily that is expressed
both  on  antigen-presenting  cells  and  various
nonhematopoietic cells [10-13]. Its counter-receptor, CD154
(CD40 ligand), is expressed on activated CD4+ T cells and
platelets, and is also present in soluble form in plasma [10,
11]. CD40-CD154 interaction is central to regulation of both
cellular and humoral immunity [10,11,14]. In addition, CD40-
CD154 signaling activates inflammation. Indeed, the CD40-
CD154  pathway  is  pivotal  for  the  development  and
progression of atherosclerosis, graft rejection, and various
autoimmune disorders [15]. Recent studies uncovered that
retinal  inflammatory  infiltration  and  neurovascular
degeneration after acute retinal ischemia are driven by CD40
[16].
Despite important advances, we still have an incomplete
understanding of the pathogenesis of retinopathies. An assay
that  can  readily  quantitate  expression  of  surface  and
intracellular  molecules  involved  in  retinal  injury  would
further our understanding of the pathogenesis of various forms
of retinal diseases. Herein we report on a flow cytometric
method to identify various retinal cell subsets and quantitate
proinflammatory molecules in these cells.
Molecular Vision 2009; 15:1383-1389 <http://www.molvis.org/molvis/v15/a146>
Received 24 April 2009 | Accepted 21 June 2009 | Published 17 July 2009
© 2009 Molecular Vision
1383METHODS
Animals:  Male  C57BL/6  (B6)  mice  were  obtained  from
Jackson  Laboratories  (Bar  Harbor,  ME).  Animals  had  a
weight of 25 to 30 g (10–14 week) when used for experiments.
Experiments were approved by the Institutional Animal Care
and  Use  Committee  of  Case  Western  Reserve  University
School of Medicine.
Isolation of primary retinal cells: Mice were anesthetized and
perfused through the heart with phosphate buffer serum (PBS,
Mediatech, Manassas, VA) to remove blood from the eyes
before  organ  collection.  Mice  were  anesthetized  by
intramuscular  injection  of  0.15  ml  of  Triple  Cocktail
containing ketamine, xylazine, and acepromazine. This was
followed by perfusion through the heart. Retinas were isolated
and minced following by digestion in a solution containing
15  IU/ml  papain  and  15  μg/ml  DNase  (Worthington
Biochemicals, Freehold, NJ) for 30 min at 37 °C. Tissue was
dissociated by gentle pipetting and passed through a 40 μm
cell  strainer.  Flow-through  was  mixed  with  Fetal  bovine
serum (FBS; HyClone Laboratories Inc. South Logan, UT)
and washed. Tissue trapped by the strainer was digested with
1 mg/ml collagenase type I (Worthington Biochemicals) for
30 min at 37 °C to free endothelial cells. After dissociation
and mixing with FBS, cells were washed once in DMEM
(Mediatech)  with  10%  FBS  for  5  min  at  300  g  at  room
temperature.  Cells  obtained  after  papain-DNase  and
collagenase treatments were pooled and counted. Viability of
the cells was consistently greater than 90% as assessed by
trypan blue exclusion. Cells were kept on ice in Ca2+, Mg2+-
free PBS (Mediatech) until immunofluorescent labeling.
Flow cytometry: Suspensions of primary retinal cells from
two to five mice were pooled and were incubated for 10 min
with  immunoglobulin  constant  Fragment  (Fc)-receptor
blocking antibody (Fc block: anti-CD16/CD32, clone 2.4G2;
BD Biosciences, San Jose, CA) to reduce nonspecific binding
of  antibodies  used  for  flow  cytometry.  Retinal  cell
suspensions were incubated with the following antibodies:
allophycocyanin (APC)-conjugated or APC-Alexa Fluor 750-
conjugated anti-CD11b (this marker identifies microglia in
the  normal  retina;  eBiosciences,  San  Diego,  CA),  APC-
conjugated  anti-CD31  (to  detect  endothelial  cells;
eBiosciences),  APC-conjugated  anti-CD105  (to  detect
endothelial cells; R&D Systems, Minneapolis, MN), APC-
conjugated  anti-Thy1  (to  detect  ganglion  neurons;
eBiosciences) or appropriate isotype control antibodies. For
detection  of  intracellular  markers,  cells  were  fixed  and
permeabilized by using IntraPrep permeabilization reagent
(Beckman Coulter, Hialeah, FL) following manufacturer’s
instructions  [17].  Thereafter,  cells  were  stained  with
fluorescein isothiocyanate (FITC)-conjugated anti-vimentin
(to detect Müller cells; Santa Cruz Biotechnologies, Santa
Cruz, CA), phycoerythrin (PE)-conjugated anti-glial fibrillary
acidic protein (GFAP; this marker identifies astrocytes in the
normal mouse retina; Santa Cruz), anti-rhodopsin mAb (to
detect photoreceptors; 1D4 and C7, gifts from Dr. Krzysztof
Palczewski,  Case  Western  Reserve  University,  Cleveland,
OH) followed by APC-conjugated donkey F(ab’)2 fragment
anti-mouse  IgG  Ab  (eBiosciences)  or  appropriate  isotype
control  Abs.  Cells  were  analyzed  after  fixation  with  1%
paraformaldehyde. In certain experiments, cells were jointly
stained with PE-conjugated or FITC-conjugated anti-CD40
mAb (BD Biosciences), PE-conjugated or FITC-conjugated
anti-ICAM-1  mAb  (eBiosciences)  or  Alexa  Fluor  647-
conjugated anti-NOS2 Ab (Santa Cruz). Expression of CD40
or  ICAM-1  was  analyzed  on  gated  CD11b+,  CD31+,
CD105+,  GFAP+,  rhodopsin+,  vimentin+,  or  Thy-1+  cells.
Expression of NOS2 was analyzed in permeabilized CD11b+
cells. The average levels of expression of CD40, ICAM-1, and
NOS2 in various retinal cell subsets are expressed as corrected
Mean Fluorescence Intensity (cMFI). This was obtained by
subtracting fluorescence obtained with isotype control Ab
from  the  fluorescence  obtained  with  Abs  against  CD40,
ICAM-1,  or  NOS2.  Flow  cytometry  data  acquisition  was
performed using a LSR II and running FACSDiva software
(Becton Dickinson, San Jose, CA). FlowJo software (Tree
Star Inc., Ashland, OR) was used for data analysis. In certain
experiments,  vimentin+,  and  rhodopsin  high  (rhodopsinhi)
events were sorted using a FACSAria (Becton Dickinson).
Sorted events were analyzed by light microscopy.
Mouse endothelial cells were used to determine whether
enzymatic treatment affects expression of surface markers.
Mouse high endothelial venule cells c (mHEVc) [18] stably
transfected with CD40-encoding plasmid [19] were detached
by exposure to Versene (Invitrogen, Carlsbad, CA) for 5 min.
Cell  suspensions  were  then  incubated  with  or  without
enzymatic cocktail as we have described in this paper. Cells
were subsequently incubated with fluorescent antibodies and
were subjected to flow cytometry analysis
Model of retinal ischemia and reperfusion: Retinal ischemia
was induced as we previously described [1,16]. The anterior
chamber of one eye was cannulated with a 30 gauge needle
attached to a line infusing normal saline. Intraocular pressure
(IOP) was measured by a handheld tonometer (TONO Pen;
Medtronic Solan, Jacksonville, FL) and pressure in the eye
was regulated to 80 mmHg to 90 mmHg with a pressure
infuser (Infu-surg; Ethox Corp., Buffalo, NY) and maintained
for 90 min. The other eye of the same animal was set up as a
control. After ischemia, the needle was withdrawn, IOP was
normalized,  and  reflow  of  the  retinal  circulation  was
documented  visually.  Mice  were  euthanized  with  triple
cocktail one or seven days after I-R injury and retinal cell
suspensions were processed for flow cytometry.
Statistical analysis: All results were expressed as the mean
±standard error of the mean. Data were analyzed by two-tailed
Student’s  t  test.  Differences  were  considered  statistically
significant at p<0.05.
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Detection of ICAM-1 and CD40 on various retinal cells by
flow cytometry: Enzymatic digestion was performed to obtain
retinal  single  cell  suspensions.  Pilot  experiments  were
conducted to determine whether enzymatic treatment impairs
expression of surface markers. Cell suspensions of CD40+
mouse  endothelial  cells  (mHEVc)  were  treated  with  or
without enzymatic cocktail as described in Methods followed
by flow cytometric analysis of cell surface markers. The levels
of expression (cMFI) of CD31, CD40 and ICAM-1 were not
affected by enzymatic treatment. The levels of expression for
these molecules were as follows: No enzymatic treatment:
CD31=105±14,  CD40=99±7,  ICAM-1=82±4;  Enzymatic
treatment: CD31=100±1, CD40=82±8, ICAM-1=78±1 (n=3;
p>0.5). Thus, the protocol of enzymatic digestion appeared
unlikely  to  significantly  affect  expression  of  surface
molecules.
Single-cell  suspensions  were  obtained  from
exsanguinated  retinas.  Each  retina  yielded  on  average
2.01±0.20x106 cells (n=15). We applied flow cytometry to
identify various cell types in the normal mouse retina. We used
a  panel  of  antibodies  against  markers  shown  by
immunofluorescence to be expressed by different cell subsets
in  the  normal  mouse  retina:  CD11b  for  microglia/
macrophages [20], CD31 for endothelial cells [21], GFAP for
astrocytes [21], rhodopsin for photoreceptors [22,23], Thy-1
for  ganglion  neurons  [24],  and  vimentin  for  Müller  cells
[21]. We started by examining photoreceptors and Müller
cells, two major cell types in the retina. Retinal cells were
permeabilized to detect intracellular rhodopsin and vimentin.
Staining  with  anti-rhodopsin  or  anti-vimentin  antibodies
revealed expression of these intracellular markers as shown
in Figure 1A. Regardless of the anti-rhodopsin antibody used
(1D4 or C7), the expression of rhodopsin was bimodal (Figure
1A). Sorting of rhodopsinhi events revealed that they consisted
of  rod-like  structures  of  1  μm  in  diameter  (not  shown),
morphological features consistent with outer segments, the
portion of the photoreceptors that expresses high levels of
rhodopsin. Flow cytometry also examines two forms of light
scatter:  forward  scatter  (FSC)  and  side  scatter  (SSC),
parameters  that  indicate  the  size  and  cell  granularity
respectively. Figure 1B reveals the FSC and SSC pattern of
rhodopsin+ and vimentin+ retinal cells. Similarly, gating on
CD11b+,  CD31+,  GFAP+,  and  Thy-1+  cells  revealed  the
various patterns of FSC and SSC for each cell population
(Figure 1C). The phenotypic composition of the cells released
from the retina after enzymatic digestion is shown in Figure
2. Results were similar regardless of whether surface markers
were  assessed  on  permeabilized  versus  non-permeabilized
cells (not shown). These studies also include staining with a
mAb against CD105, a marker for endothelial cells.
ICAM-1 is an adhesion molecule that plays a pivotal role
in recruitment of leukocytes to the retina and the development
of vascular histopathology [2,5]. In addition, recent studies
identified  CD40  as  an  important  regulator  of  retinal
inflammation and neurovascular degeneration [16]. We used
flow cytometry to examine the expression of these molecules
on various retinal cells. Cell suspensions were stained with
anti-ICAM-1 or anti-CD40 mAb plus either antibodies against
CD11b,  CD31,  CD105,  GFAP,  rhodopsin,  Thy-1,  or
vimentin. Varying levels of ICAM-1 were detected on all the
subsets  of  retinal  cells  examined  (Figure  3).  ICAM-1
expression did not appear to be homogenous within rhodopsin
+ and Thy-1+ cell populations. CD40 was detected only on
CD11b+  (microglia/macrophages),  CD31+(endothelial),
Thy-1+(ganglion), and vimentin+ cells (Müller) cells (Figure
4). Despite the typical low levels of expression, CD40 is an
important  mediator  of  inflammation  [15].  These  results
indicate that flow cytometry allows quantitation of surface
molecules involved in retinal inflammatory disorders.
Figure 1. Flow cytometric analysis of retinal cell suspensions. A:
Single-cell suspensions obtained after enzymatic digestion of retinas
were permeabilized and stained with antibodies against rhodopsin
and  vimentin  (thick  lines)  or  isotype  control  antibodies  (shaded
areas) as described in Methods. The gate R2 in histograms reveal
events  that  stained  with  either  anti-rhodopsin  or  anti-vimentin
antibodies. B: The forward scatter (FSC) versus side scatter (SSC)
profile of retinal cells is shown. Red dots represent vimentin+ or
rhodopsin+ events as defined by gating criteria (R2) shown in panel
A. C: Single-cell suspensions were stained with antibodies against
CD11b,  CD31,  and  Thy-1  to  detect  surface  expression  of  these
molecules.  Permeabilized  cells  were  incubated  with  anti-GFAP
antibody. Red dots represent events that stained with either CD11b
or Thy-1 as indicated. Due to low frequency of CD31+ and GFAP+
events,  cells  that  did  not  stain  with  anti-CD31  and  anti-GFAP
antibodies were removed from the dot plots, thus enabling easier
identification  of  CD31+  and  GFAP+  events.  Results  are
representative of six to nine independent experiments.
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Next,  we  examined  if  flow  cytometry  can  quantify
upregulation of ICAM-1. Endothelial and Müller cells are
major components of the blood-retinal barrier [25] and thus,
are  likely  to  be  involved  in  the  adhesion-dependent
recruitment of leukocytes to the retina. Ischemia-Reperfusion
Figure 2. Phenotypic composition of retinal cell suspensions. Single-
cell suspensions were stained with the indicated antibodies. Data are
shown as the mean±SEM from six to nine independent experiments.
Figure 3. Expression of ICAM-1 on various subsets of retinal cells.
Single-cell suspensions were stained with isotype control or with
anti-ICAM-1  mAb.  Cells  were  coincubated  with  antibodies  that
detect cell surface expression of CD11b, CD31, CD105, or Thy-1
(A),  or  cells  were  permeabilized  followed  by  incubation  with
antibodies against rhodopsin and vimentin (B) or GFAP (C) to detect
intracellular  expression  of  these  markers.  PE-conjugated  anti-
ICAM-1 mAb was used in all conditions except when staining GFAP
+ cells, where FITC-conjugated mAb was used instead. The average
expression of ICAM-1 (cMFI) on gated CD11b+, CD31+, CD105+,
Thy-1+, GFAP+, rhodopsin+, and vimentin+ events were calculated
as described in Methods. Data are shown as the mean±SEM from
three to four independent experiments. D: Representative dot plots
of ICAM-1 versus various markers are shown. Red dots represent
cells that expressed these markers. Horizontal and vertical lines
represent gates obtained with isotype control antibodies.
(I-R) of the retina results in upregulation of ICAM-1 mRNA
[1].  However,  it  is  not  known  if  ICAM-1  protein  levels
increase in retinal endothelial and Müller cells after I-R. We
used a well established model of I/R-induced retinal injury
(transient elevation of IOP) [1] to examine this possibility.
Retinal  cells  from  ischemic  and  nonischemic  eyes  were
stained  with  isotype  control  antibodies  or  with  an  anti-
ICAM-1  mAb  plus  either  anti-CD105  or  anti-vimentin
antibodies. CD105+ and vimentin+ cells from ischemic retinas
upregulated ICAM-1 compared to cells from control retinas
(Figure  5;  p=0.03;  n=3).  These  results  indicate  that  flow
cytometry  allows  measuring  upregulation  of  a  surface
molecule involved in retinal inflammatory processes.
Upregulation  of  NOS2  in  retinal  microglia  after  retinal
ischemia/reperfusion:  NOS2  plays  an  important  role  in
Figure 4. Expression of CD40 on various subsets of retinal cells.
Single-cell suspensions were stained with isotype control or with
anti-CD40 mAb. Cells were coincubated with antibodies that detect
cell surface expression of CD11b, CD31, CD105, or Thy-1 (A), or
cells were permeabilized followed by incubation with antibodies
against  rhodopsin  and  vimentin  (B),  or  GFAP  (C)  to  detect
intracellular expression of these markers. PE-conjugated anti-CD40
mAb was used in all conditions except when staining GFAP+ cells,
where  FITC-conjugated  mAb  was  used  instead.  The  average
expression of CD40 (cMFI) on gated CD11b+, CD31+, CD105+,
Thy-1+, GFAP+, rhodopsin+, and vimentin+ events were calculated
as described in Methods. Data are shown as the mean±SEM from
three to four independent experiments.  CD40  was not detected on
rhodopsin  and GFAP  cells. D: Representative dot  plots of  CD40
versus  various  markers  are  shown. Red  dots  represent  cells  that
expressed  these  markers.  Horizontal  and  vertical  lines  represent
gates obtained with isotype control antibodies.
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+ +neurovascular degeneration in retinopathies including those
mediated by acute ischemia and diabetes [1,7,9,26,27]. I/R-
induced  retinal  injury  results  in  NOS2  upregulation  in
microglia at 5 to 7 days post-I/R, time points where NOS2+
peripheral blood neutrophils (that can also express CD11b)
are no longer detected in the retina [27]. We used retinas at
seven days postischemia to examine whether flow cytometry
can detect upregulation of NOS2. Retinal cells from ischemic
and nonischemic eyes were stained with an anti-CD11b mAb
followed by permeabilization and staining with an anti-NOS2
antibody. As shown in Figure 6, NOS2 was upregulated within
CD11b+ cells from ischemic retinas (p<0.01; n=3). These
results indicate that flow cytometry allows quantitation of an
intracellular  molecule  involved  in  retinal  inflammatory
processes.
DISCUSSION
A complex mixture of inflammatory mediators is increasingly
recognized to be important for the development of various
retinopathies.  We  report  on  the  use  of  flow  cytometry  to
examine  expression  of  surface  and  intracellular
proinflammatory molecules involved in the pathogenesis of
retinal  disorders.  This  method  is  quantitative  and  utilizes
antibodies  against  markers  previously  demonstrated  to
identify microglia/macrophages, endothelial cells, astrocytes,
photoreceptors, ganglion cells, and Müller cells in the normal
mouse retina [20-24]. Thus far, we have not identified an
antibody that is suitable to detect amacrine neurons, cone
photoreceptors,  bipolar,  and  horizontal  cells  by  flow
cytometry.  In  contrast  to  other  markers,  expression  of
rhodopsin was bimodal. This is likely explained by the fact
that the outer segments of the photoreceptors have higher
concentrations of rhodopsin than the inner segment of these
Figure 5. Upregulation of ICAM-1 on CD105+ and vimentin+ cells
after  ischemia  or  reperfusion.  One  eye  from  each  mouse  was
subjected to ischemia- reperfusion (I-R). Nonischemic eyes were
used as controls. Eyes were obtained 1 day after I-R. Retinal cell
suspensions  were  stained  with  isotype  control  antibodies,  anti-
CD105, or anti-vimentin antibodies plus an anti-ICAM-1 antibody.
Expression of ICAM-1 (cMFI) was calculated on gated CD105+ and
vimentin+  cells.  Data  are  shown  as  the  mean±SEM  from  three
independent experiments.
cells,  and  rhodopsinhi  events  have  morphological  features
consistent  with  outer  segments.  Rhodopsinlo  events  likely
represent photoreceptor cells with outer segments sheared off
in which only inner segments remain.
Immunohistochemistry studies reported constitutive low-
level expression of ICAM-1 in the normal retina [28,29] and
upregulation of ICAM-1 in the retinal vasculature of patients
with diabetes [4]. Those studies did not identify the cell types
that expressed ICAM-1. Here we show that endothelial cells,
Müller  cells,  microglia/macrophages,  astrocytes,  ganglion
cells,  and  photoreceptors  express  ICAM-1.  Of  relevance,
ICAM-1  has  been  detected  in  vitro  in  cultured  glia  and
neurons as well as in vivo in the external limiting membrane
of the retina and photoreceptor aggregates in patients with
neovascular age related macular degeneration [29-31]. The
latter  findings  suggest  that  ICAM-1  expression  may  be
involved in the pathogenesis of this disease.
I-R has been shown to lead to ICAM-1 upregulation [1,
3]. However, the cell types that exhibit increased ICAM-1 in
response to I-R have remained unknown. Our studies revealed
that  both  endothelial  cells  and  Müller  cells  upregulate
ICAM-1  after  I-R.  This  work  does  not  rule  out  ICAM-1
upregulation in other retinal cells. Upregulation of ICAM-1 is
likely relevant to the pathogenesis of I-R-induced retinopathy
since the level of ICAM-1 expression regulates the degree of
leukocyte recruitment in inflammation.
NOS2  is  involved  in  the  pathogenesis  of  various
retinopathies including retinal disease caused by I-R [7,8]. We
report  that  flow  cytometry  can  quantitate  expression  of
intracellular  NOS2  after  I-R.  The  fact  that  CD11b+  cells
become  NOS2+  after  I-R  confirms  the  previous
immunohistochemical  studies  that  strongly  suggested
acquisition of NOS2 expression by microglia after I-R [27].
We were unable to detect NOS2 in Müller cells at seven days
Figure  6.  Upregulation  of  NOS2  in  retinal  CD11b+  cells  after
ischemia or reperfusion. One eye from each mouse was subjected to
ischemia-reperfusion (I-R). Nonischemic eyes were used as controls.
Eyes were obtained seven days after I-R. Retinal cell suspensions
were stained with isotype control or an anti-CD11b mAb followed
by  permeabilization  and  staining  with  anti-NOS2  antibody.
Expression of NOS2 (cMFI) was calculated on gated CD11b+ cells.
Data  are  shown  as  the  mean±SEM  from  three  independent
experiments.
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rule out the possibility that other retinal cells acquire NOS2
expression after I-R.
The flow cytometry assay was developed to quantitate
expression of molecules involved in retinal diseases and was
not  intended  to  provide  an  accurate  assessment  of  the
phenotypic composition of cells within the retina. Indeed, the
composition of cell suspensions obtained in this study appears
to  differ  from  the  phenotypic  composition  estimated  by
microscopic  evaluation  of  the  mouse  retina  [32].  This
discrepancy could be explained by the lack of release of all
retinal cells by enzymatic treatment and by cell loss after
trapping cell clumps with the cell strainer used before flow
cytometric analysis. In addition, it should be noted that cell
fragmentation can occur during flow sorting. For example,
sorting of vimentin+ events revealed that approximately 25%
of  the  events  appeared  to  represent  fragments  of  cells  as
assessed by light microscopy. In addition, cellular markers
should  be  selected  carefully  since  certain  conditions  may
affect the cells that express them (for example expression of
CD11b or Thy-1 when neutrophils or T cells respectively
infiltrate  the  retina).  Despite  these  caveats,  the  studies
performed using the model of I-R-induced retinopathy clearly
indicate that flow cytometry is useful to quantitate changes in
levels of expression of proinflammatory proteins in various
retinal cells.
In  summary,  flow  cytometry  can  readily  measure
expression of surface and intracellular molecules ex vivo in
various retinal cells without lengthy purification protocols.
While immunohistochemistry is useful for examination of
topographical  distribution  of  proteins,  flow  cytometry
provides  a  methodology  where  protein  expression  can  be
easily quantitated and where multiple proteins can be readily
examined simultaneously by using antibodies conjugated with
different fluorochromes. Flow cytometry may enable future
studies to improve our understanding of the regulation of
retinal diseases.
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